

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
08 May 2025 (08.05.2025)



(10) International Publication Number
WO 2025/096435 A1

(51) International Patent Classification:

A61K 39/395 (2006.01) C07K 14/47 (2006.01)
A61K 38/17 (2006.01) C07K 16/18 (2006.01)
A61P 13/12 (2006.01) A61K 39/00 (2006.01)

(21) International Application Number:

PCT/US2024/053402

(22) International Filing Date:

29 October 2024 (29.10.2024)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/546,330 30 October 2023 (30.10.2023) US
63/700,980 30 September 2024 (30.09.2024) US

(71) Applicant: **Q32 BIO INC.** [US/US]; 830 Winter Street,
Waltham, MA 02451 (US).

(72) Inventors: **CAMPAGNA, Jason**; c/o Q32 Bio Inc., 830
Winter Street, Waltham, MA 02451 (US). **VIOLETTE,
Shelia Marie**; c/o Q32 Bio Inc., 830 Winter Street,
Waltham, MA 02451 (US). **WU, Hong**; c/o Q32 Bio Inc.,
830 Winter Street, Waltham, MA 02451 (US).


(74) Agent: **LU, Yu** et al.; McCarter & English, LLP, 265
Franklin Street, Boston, MA 02110 (US).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG,
KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY,
MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA,
NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO,
RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,
ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, CV,
GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST,
SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ,
RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ,
DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT,
LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE,
SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,
GQ, GW, KM, ML, MR, NE, SN, TD, TG).

(54) Title: TREATMENT OF COMPLEMENT-ASSOCIATED RENAL DISEASES

FIG. 1



(57) Abstract: Provided are compounds, compositions and methods for treating a renal disease characterized by dysregulation of the complement system and/or characterized by C3d deposit in kidney, in patients in need thereof.

[Continued on next page]

Declarations under Rule 4.17:

- *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*
- *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

Published:

- *with international search report (Art. 21(3))*
- *with sequence listing part of description (Rule 5.2(a))*